Cas:28320-32-3 2,7-Dibromo-9,9-dimethylfluorene manufacturer & supplier

Chemical Name:2,7-Dibromo-9,9-dimethylfluorene

CAS.NO:28320-32-3

Synonyms:2,7-Dibromo-9,9-dimethylfluoren;2,7-Dibromo-9,9-dimethyl fluorene;2,7-Dibromo-9,9-dimethyl-9H-fluorene;9,9-Dimethyl-2,7-Dibromofluorene;L B656 HHJ EE H1 H1 KE;9H-Fluorene, 2,7-dibromo-9,9-dimethyl-;2,7-DibroMo-9,9-diMethylfluorene;MFCD00099471

Molecular Formula:C₁₅H₁₂Br₂

Molecular Weight:352.064

HS Code:

Physical and Chemical Properties:

Melting point:180ºC

Boiling point:401.8±38.0 °C at 760 mmHg

Density:1.6±0.1 g/cm3

Index of Refraction:1.635

PSA:

Exact Mass:349.930573

LogP:6.74

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 3077 9 / PGIII

Packing Group:

Contact us for information like 2,7-Dibromo-9,9-dimethylfluoren chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00099471 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00099471 Use and application,MFCD00099471 technical grade,usp/ep/jp grade.

Related News: As a result, the team identified and prioritized studies that would provide the necessary product and process understanding needed to develop a control strategy, ensure the reproducibility of the product, and meet its intended safety, efficacy, stability, and performance profile regardless of the manufacturing scale. 2-(3-Chloro-10H-pyrido[3,2-b][1,4]benzothiazin-10-yl)-N,N-dimethy l-1-propanamine hydrochloride (1:1) manufacturers The announcement comes on top of Recipharm’s move into Morocco, which was fueled by local pledges of $500 million. The new facility under construction and due for completion in 2023 will employ 300 and have a capacity of 300 million units annually. 2,2′-((1,1′,7,7′-tetrahydroxy-5,5′-diisopropyl-6,6′-dimethoxy-3,3′-dimethyl-[2,2′-binaphthalene]-8,8′-diyl)bis(methaneylylidene))bis(hydrazine-1-carbothioamide) suppliers The European Medicines Agency on Friday rejected Kyowa Kirin’s Parkinson’s disease drug Nouryant (istradefylline), which the US FDA approved in 2019 under the brand name Nourianz. 3-sec.-Butyl-6-cyclopentyl-uracil vendor & factory.